Kalpit Patel
Stock Analyst at Wolfe Research
(2.12)
# 3,146
Out of 5,182 analysts
77
Total ratings
42.31%
Success rate
-3.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Downgrades: Peer Perform | n/a | $52.87 | - | 2 | Apr 7, 2026 | |
| GMAB Genmab | Initiates: Outperform | $32 | $26.45 | +20.98% | 1 | Mar 27, 2026 | |
| OLMA Olema Pharmaceuticals | Initiates: Peer Perform | n/a | $14.32 | - | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Initiates: Peer Perform | n/a | $266.04 | - | 1 | Mar 27, 2026 | |
| ONC BeOne Medicines AG | Initiates: Outperform | $340 | $293.86 | +15.70% | 1 | Mar 27, 2026 | |
| CORT Corcept Therapeutics | Upgrades: Peer Perform | n/a | $51.42 | - | 2 | Mar 26, 2026 | |
| AVBP ArriVent BioPharma | Maintains: Buy | $37 → $45 | $29.99 | +50.05% | 2 | Mar 23, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $80.71 | +44.96% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $0.98 | +205.90% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $9.77 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $14.34 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $20.98 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $16.12 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $46.37 | -9.41% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $139.48 | -46.23% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $125.65 | -12.46% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $5.20 | +130.77% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $4.80 | +191.67% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $29.40 | -18.37% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.58 | +121.52% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $5.84 | +54.11% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.76 | +110.08% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $10.30 | +288.35% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $2.79 | +7.53% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $13.42 | +49.03% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.19 | +615.99% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $19.11 | +88.38% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.50 | +5,900.00% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.15 | +737.21% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.10 | +354.55% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $11.61 | +761.33% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $28.19 | +166.05% | 2 | Sep 3, 2021 |
Soleno Therapeutics
Apr 7, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $52.87
Upside: -
Genmab
Mar 27, 2026
Initiates: Outperform
Price Target: $32
Current: $26.45
Upside: +20.98%
Olema Pharmaceuticals
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $14.32
Upside: -
Krystal Biotech
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $266.04
Upside: -
BeOne Medicines AG
Mar 27, 2026
Initiates: Outperform
Price Target: $340
Current: $293.86
Upside: +15.70%
Corcept Therapeutics
Mar 26, 2026
Upgrades: Peer Perform
Price Target: n/a
Current: $51.42
Upside: -
ArriVent BioPharma
Mar 23, 2026
Maintains: Buy
Price Target: $37 → $45
Current: $29.99
Upside: +50.05%
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $80.71
Upside: +44.96%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.98
Upside: +205.90%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $9.77
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $14.34
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $20.98
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $16.12
Upside: -
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $46.37
Upside: -9.41%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $139.48
Upside: -46.23%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $125.65
Upside: -12.46%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.20
Upside: +130.77%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $4.80
Upside: +191.67%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $29.40
Upside: -18.37%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.58
Upside: +121.52%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.84
Upside: +54.11%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.76
Upside: +110.08%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $10.30
Upside: +288.35%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $2.79
Upside: +7.53%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $13.42
Upside: +49.03%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.19
Upside: +615.99%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $19.11
Upside: +88.38%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.50
Upside: +5,900.00%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.15
Upside: +737.21%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.10
Upside: +354.55%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $11.61
Upside: +761.33%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $28.19
Upside: +166.05%